Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four Different Vaccination Schedules

Clinical trial NCT00848029 · COMPLETED

Trial details

NCT number: NCT00848029
Sponsor: Novartis Vaccines
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Pre-pandemic Influenza Vaccine

Start date: 2008-11-01
Primary completion: 2009-06-01
Enrollment: 240

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.